New Product Planning Plays a Critical Role for Future Research & Development Success

CHAPEL HILL, N.C., July 19 /PRNewswire/ -- New Product Planning (NPP) groups will be a critical component for focusing new product development and optimizing product portfolios. The expected reigning in of research and development costs for biopharmaceutical companies, coupled with anemic pipelines, opens the door for NPP groups to have a growing impact in aligning scientific and commercial interests, prioritizing R&D resources and helping to drive an integrated view of development projects.

"The New Product Planning function will likely evolve from a strategic consultative role to one that's tightly tied to the success of a development compound and franchise strategy," one executive sums up during an in-depth interview.

"Driving Growth Through Planning, Structure and Activities: Best Practices in Pharmaceutical New Product Planning," a report derived from primary research conducted by Best Practices, LLC, identifies the structure and roles of NPP groups as well as the full set of activities that NPP groups perform across the development cycle.

Download a complimentary white paper at http://www3.best-in-class.com/rr1011.htm that includes selected best practices drawn from extensive primary research with 27 managers and executives from 25 leading companies, including Abbott, Allergan, Amgen, Daiichi Sankyo, Merck, Novartis, and Takeda.

Key topics include:

  • NPP group structures, roles and responsibilities
  • Interactions and optimal working relationships between Regional and Global NPP groups
  • Examining the full set of activities groups perform, their timing, intended outcomes, and value for the organization
  • The future of the NPP function

The full 72-page report contains more than 40 benchmark metrics and 30 executive narratives, providing new product development leaders a better understanding the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolve as a company matures.

For more information on this study or other recent primary research studies, contact us at 919.403.0251 or at [email protected].  

BEST PRACTICES, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for more than 17 years; our clients include 48 out of the top 50 pharmaceutical companies.

SOURCE Best Practices, LLC

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."